Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRII-5395, Sintilimab, and Bevacizumab in Advanced HBV-Related Hepatocellular Carcinoma
NCT07557251Phase 1Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of BRII-5395 in hepatocellular carcinoma (HCC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose-Limiting Toxicities at 30 days, Adverse Events at 30 days and 1 more. Started Aug 2026; status: recruiting.
02
Drugs
BRII-5395
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07557251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07557251.